Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Multicenter, Observer-Blinded, Randomized, Active Controlled, Immune Non-inferiority and Safety Study of Vi-DT Vaccine Compared to Typbar TCV in Healthy 6 Months-45 Years Aged Nepalese Participants.

Next Previous
Trial Profile

A Phase III Multicenter, Observer-Blinded, Randomized, Active Controlled, Immune Non-inferiority and Safety Study of Vi-DT Vaccine Compared to Typbar TCV in Healthy 6 Months-45 Years Aged Nepalese Participants.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 23 Feb 2024 According to a SK Bioscience media release, the SKYTyphoid has received an export license from the Korean Ministry of Food and Drug Safety in 2022, based on the results of this global clinical study. The company has obtained prequalification (PQ) certification from the World Health Organization (WHO) for, SKYTyphoid. The WHO PQ system evaluates the manufacturing process, quality, and clinical trial results of a vaccine according to strict criteria to certify its safety and efficacy.
  • 01 Apr 2022 Results published in The Lancet Infectious Diseases
  • 26 Nov 2019 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top